| scholarly article | Q13442814 |
| P50 | author | Peter Carl Wollan | Q103319056 |
| Barbara P Yawn | Q104691090 | ||
| L. Joseph Melton | Q112619624 | ||
| Nicholas Talley | Q7026286 | ||
| P2093 | author name string | Lydick E | |
| Locke GR 3rd | |||
| P2860 | cites work | The epidemiology of irritable bowel syndrome in North America: a systematic review | Q34791832 |
| The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review | Q34993716 | ||
| AGA technical review on irritable bowel syndrome | Q35010302 | ||
| Epidemiological aspects of irritable bowel syndrome in Europe and North America. | Q52959814 | ||
| One-year follow-up of newly diagnosed irritable bowel syndrome patients | Q78196000 | ||
| Do published guidelines for evaluation of irritable bowel syndrome reflect practice? | Q21261904 | ||
| Detection of colorectal tumor and inflammatory bowel disease during follow-up of patients with initial diagnosis of irritable bowel syndrome | Q33898224 | ||
| Insights into the pathophysiology and mechanisms of constipation, irritable bowel syndrome, and diverticulosis in older people | Q34030234 | ||
| Irritable bowel syndrome: a little understood organic bowel disease? | Q34150284 | ||
| Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors | Q34262536 | ||
| The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review | Q34521232 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | United States of America | Q30 |
| irritable bowel syndrome | Q838966 | ||
| P304 | page(s) | 1025-1031 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Alimentary Pharmacology & Therapeutics | Q4726656 |
| P1476 | title | Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population. | |
| P478 | volume | 19 |
| Q37874894 | All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome |
| Q35962097 | Canadian Digestive Health Foundation Public Impact Series 3: irritable bowel syndrome in Canada. Incidence, prevalence, and direct and indirect economic impact |
| Q38919181 | Common Functional Gastroenterological Disorders Associated With Abdominal Pain |
| Q88216225 | Cost Effectiveness of Biomarker Tests for Irritable Bowel Syndrome With Diarrhea: A Framework for Payers |
| Q57465652 | Cost-effectiveness of interventions for medically unexplained symptoms: A systematic review |
| Q33283471 | Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). |
| Q46138993 | Development and validation of the irritable bowel syndrome scale under the system of quality of life instruments for chronic diseases QLICD-IBS: combinations of classical test theory and generalizability theory |
| Q33717205 | Developmental biology of the enteric nervous system: pathogenesis of Hirschsprung's disease and other congenital dysmotilities |
| Q49141168 | Effect of repetitive transcranial magnetic stimulation on rectal function and emotion in humans |
| Q39012302 | Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases |
| Q58860964 | Epidemiology of irritable bowel syndrome |
| Q34626602 | Guidelines on the irritable bowel syndrome: mechanisms and practical management. |
| Q36110577 | Gut pain & visceral hypersensitivity |
| Q36348565 | Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations? |
| Q37275677 | Irritable bowel syndrome is associated with gastroesophageal reflux symptom but not erosive esophagitis |
| Q36310403 | Irritable bowel syndrome: diagnosis and pathogenesis |
| Q38192048 | Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment |
| Q38191561 | Is irritable bowel syndrome an organic disorder? |
| Q37099359 | Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas |
| Q33890440 | Prevalence and risk factors of irritable bowel syndrome in Asia |
| Q33890455 | Prevalence and risk factors of irritable bowel syndrome in healthy screenee undergoing colonoscopy and laboratory tests |
| Q39751875 | Prevalence, sociodemography, and quality of life of older versus younger patients with irritable bowel syndrome: a population-based study |
| Q37704526 | Rifaximin therapy of irritable bowel syndrome |
| Q31062841 | Risk of inflammatory bowel disease following a diagnosis of irritable bowel syndrome |
| Q36594630 | The Epidemiology of Irritable Bowel Syndrome in the US Military: Findings from the Millennium Cohort Study |
| Q85064011 | The Incidence and Gastrointestinal Infectious Risk of Functional Gastrointestinal Disorders in a Healthy US Adult Population |
| Q38032174 | The chronic gastrointestinal consequences associated with campylobacter |
| Q36222107 | The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review |
| Q37577760 | The epidemiology of irritable bowel syndrome |
| Q40466962 | The epidemiology of irritable bowel syndrome: Symptom development over a 3-year period in Denmark. A prospective, population-based cohort study. |
| Q40516224 | The incidence rate and characteristics of clinically diagnosed defecatory disorders in the community |
| Q41009017 | The risk of irritable bowel syndrome in patients with endometriosis during a 5-year follow-up: a nationwide population-based cohort study |
Search more.